Alectinib maintenance therapy following cord blood transplantation for relapsed pediatric anaplastic large cell lymphoma with central nervous system involvement

Pediatric ALK-positive anaplastic large cell lymphoma is a rare subtype of non-Hodgkin lymphoma, and approximately 30% of patients relapse following treatment with conventional chemotherapy. Alectinib monotherapy has demonstrated excellent activity in relapsed and refractory ALCL, but its role as a...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2024-11, Vol.103 (11), p.4805-4809
Main Authors: Tamefusa, Kosuke, Ishida, Hisashi, Miyahara, Daisuke, Shiwaku, Takahiro, Ochi, Motoharu, Kanamitsu, Kiichiro, Fujiwara, Kaori, Tatebe, Yasuhisa, Washio, Kana, Akiyama, Tomoyuki, Tsukahara, Hirokazu
Format: Article
Language:English
Subjects:
Allografts
Ascites
Bone marrow
Carbazoles - administration & dosage
Carbazoles - therapeutic use
Case Report
Case reports
Central Nervous System Neoplasms - drug therapy
Central Nervous System Neoplasms - therapy
Chemotherapy
Child
Cord Blood Stem Cell Transplantation
Cytokines
Drug stores
Female
Fever
Graft versus host disease
Hematology
Humans
Lymphoma
Lymphoma, Large-Cell, Anaplastic - drug therapy
Lymphoma, Large-Cell, Anaplastic - therapy
Magnetic resonance imaging
Maintenance Chemotherapy
Male
Medical prognosis
Medicine
Medicine & Public Health
Nervous system
Oncology
Patients
Pediatrics
Piperidines - therapeutic use
Recurrence
Remission (Medicine)
Tomography
Toxicity
Transplants & implants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pediatric ALK-positive anaplastic large cell lymphoma is a rare subtype of non-Hodgkin lymphoma, and approximately 30% of patients relapse following treatment with conventional chemotherapy. Alectinib monotherapy has demonstrated excellent activity in relapsed and refractory ALCL, but its role as a maintenance therapy after hematopoietic cell transplantation is unclear. We experienced a relapse case of pediatric ALK-positive ALCL with central nervous system involvement treated with alectinib maintenance therapy following cord blood transplantation. The patient has maintained complete remission for more than 3 years after transplantation. There were no remarkable adverse effects that led to discontinuation of alectinib.
ISSN:0939-5555
1432-0584
1432-0584
DOI:10.1007/s00277-024-06000-7